Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?
New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.